Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes
Continue reading »
Home »
Results ‘encouraging’ from phase II trial for relapsed acute myeloid leukemia
There is a significant need for new treatments for patients with relapsed acute myeloid leukemia, a rare cancer of the
Continue reading »
Researchers identify experimental immunotherapy approach to target acute myeloid leukemia
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a potential way to target a subtype of acute
Continue reading »
Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia
Clinical trials at University of Colorado Cancer Center and elsewhere now result in the drug ivosidenib earning approval from the
Continue reading »
FDA approves tibsovo for acute myeloid leukemia
(HealthDay)—Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid
Continue reading »
BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
AIRPORT CITY, Israel, July 11, 2018 /PRNewswire/ — BioSight Ltd., a pharmaceutical development company focused on the development of targeted
Continue reading »
New potential target identified to fight acute myeloid leukemia
AML is not a single disease. It is a group of leukemias that develop in the bone marrow from progenitors
Continue reading »